ProPhase Labs Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de ProPhase Labs de 77.4% y 86.3% respectivamente, mientras que el BPA crecerá en un 44.4% al año.

Información clave

77.4%

Tasa de crecimiento de los beneficios

44.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.7%
Tasa de crecimiento de los ingresos	86.3%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	27 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Investors Give ProPhase Labs, Inc. (NASDAQ:PRPH) Shares A 65% Hiding

Nov 09

It's Down 65% But ProPhase Labs, Inc. (NASDAQ:PRPH) Could Be Riskier Than It Looks

Nov 09

Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Jul 03

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Mar 04

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Jan 09

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Sep 21

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

Aug 11

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Apr 07

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Jul 21

ProPhase Labs: A Stellar Quarter And Another Special Dividend

May 16

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:PRPH - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	95	6	N/A	N/A	1
12/31/2025	50	-16	N/A	N/A	1
12/31/2024	15	-24	N/A	N/A	1
9/30/2024	13	-28	-17	-14	N/A
6/30/2024	18	-26	-18	-15	N/A
3/31/2024	29	-24	-21	-17	N/A
12/31/2023	44	-17	-15	-11	N/A
9/30/2023	63	-10	-14	-10	N/A
6/30/2023	79	-4	-6	-3	N/A
3/31/2023	94	7	5	9	N/A
12/31/2022	123	18	25	29	N/A
9/30/2022	146	31	21	23	N/A
6/30/2022	131	27	13	15	N/A
3/31/2022	111	18	13	15	N/A
12/31/2021	79	6	-18	-14	N/A
9/30/2021	39	-5	-21	-16	N/A
6/30/2021	33	-2	-16	-11	N/A
3/31/2021	28	0	-16	-11	N/A
12/31/2020	15	-2	-4	-3	N/A
9/30/2020	12	-2	3	4	N/A
6/30/2020	11	-2	3	3	N/A
3/31/2020	9	-3	-2	-2	N/A
12/31/2019	10	-3	-1	-1	N/A
9/30/2019	11	-3	-1	-1	N/A
6/30/2019	11	-4	-2	-2	N/A
3/31/2019	12	-3	-1	-1	N/A
12/31/2018	13	-2	-2	-2	N/A
9/30/2018	13	-1	-3	-3	N/A
6/30/2018	14	-1	N/A	-2	N/A
3/31/2018	13	-1	N/A	-6	N/A
12/31/2017	10	-2	N/A	-3	N/A
9/30/2017	6	-3	N/A	-1	N/A
6/30/2017	5	-3	N/A	-1	N/A
3/31/2017	4	-3	N/A	2	N/A
12/31/2016	4	-4	N/A	0	N/A
9/30/2016	-6	-3	N/A	-2	N/A
6/30/2016	-3	-2	N/A	-4	N/A
3/31/2016	-2	-2	N/A	-5	N/A
12/31/2015	3	-2	N/A	-3	N/A
9/30/2015	21	-3	N/A	-4	N/A
6/30/2015	22	-7	N/A	-3	N/A
3/31/2015	22	-8	N/A	-4	N/A
12/31/2014	22	-8	N/A	-3	N/A
9/30/2014	23	-7	N/A	-1	N/A
6/30/2014	24	-2	N/A	-1	N/A
3/31/2014	24	-1	N/A	0	N/A
12/31/2013	25	0	N/A	1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que PRPH sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que PRPH sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que PRPH sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (86.3% al año) de PRPH crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (86.3% al año) de PRPH crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PRPH se prevé que sea elevada dentro de 3 años.

ProPhase Labs Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

ProPhase Labs, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Price target decreased by 7.5% to US$18.50

Price target decreased by 7.5% to US$18.50

Consensus revenue estimates fall by 16%

Consensus EPS estimates fall by 46%

Consensus estimates of losses per share improve by 19%

Recent updates

ProPhase Labs, Inc. announced delayed 10-Q filing

ProPhase Labs, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

ProPhase Labs, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Investors Give ProPhase Labs, Inc. (NASDAQ:PRPH) Shares A 65% Hiding

It's Down 65% But ProPhase Labs, Inc. (NASDAQ:PRPH) Could Be Riskier Than It Looks

ProPhase Labs, Inc. has completed a Follow-on Equity Offering in the amount of $3.0024 million.

Price target decreased by 7.5% to US$18.50

Insufficient new directors

ProPhase Labs, Inc. has completed a Follow-on Equity Offering in the amount of $3.0024 million.

ProPhase Labs Receives Non-Compliance Notice from Nasdaq Regarding Listing Rule 5605(c)(2)(A)

ProPhase Labs, Inc. announced delayed 10-Q filing

ProPhase Labs, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Price target decreased by 7.5% to US$18.50

Insufficient new directors

ProPhase Labs, Inc., Annual General Meeting, Jun 20, 2024

ProPhase Labs, Inc. to Report Q1, 2024 Results on May 09, 2024

ProPhase Labs, Inc. Unveils Project ZenQ-AI

ProPhase Labs, Inc. announced delayed annual 10-K filing

ProPhase Labs, Inc. to Report Fiscal Year 2023 Results on Mar 15, 2024

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Prophase Labs, Inc. Announces Important Developments in the Company’s Efforts to Commercialize Its Novel Be-Smart Esophageal Cancer Diagnostic Test

ProPhase Labs, Inc. Announces Preliminary Positive Results for Dietary Supplement Equivir

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Consensus revenue estimates fall by 16%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

ProPhase Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Consensus EPS estimates fall by 46%

New minor risk - Market cap size

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

First quarter 2023 earnings released: EPS: US$0.033 (vs US$0.81 in 1Q 2022)

Investor sentiment deteriorates as stock falls 15%

ProPhase Labs, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Investor sentiment deteriorates as stock falls 17%

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

Consensus estimates of losses per share improve by 19%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs, Inc. to Report Q1, 2023 Results on May 11, 2023

Investor sentiment improves as stock rises 18%

Price target increased by 13% to US$17.00

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 17%

ProPhase Labs, Inc. Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy

Chairman & CEO exercised options and sold US$2.0m worth of stock

ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly

Chairman & CEO exercised options and sold US$2.8m worth of stock

ProPhase Labs, Inc. (NasdaqCM:PRPH) acquired World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.6 million.

ProPhase Labs, Inc. Announces Executive Changes

ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for approximately $4.5 million.

Consensus forecasts updated

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% undervalued after recent price drop

ProPhase Labs, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment improved over the past week

Chairman & CEO exercised options and sold US$3.1m worth of stock

ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential

ProPhase Labs, Inc. Announces Resignation of Bill White as Chief Financial Officer

Consensus EPS estimates increase by 49%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs Q2 2022 Earnings Preview

ProPhase Labs, Inc. to Report Q2, 2022 Results on Aug 11, 2022

ProPhase Labs, Inc. (NasdaqCM:PRPH) announces an Equity Buyback for $6 million worth of its shares.

We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt

Investor sentiment deteriorated over the past week

ProPhase Labs to license two investigational cancer compounds from Global BioLife